Phenylbutazone 20% Inj.

Phenylbutazone 20% Inj. is a Kepro veterinary product developed to provide a clearly defined therapeutic or nutritional role. Its formulation is based on phenylbutazone 20% in a veterinary solution for injection. These components give the product a practical place in veterinary programs aimed at management of pain and inflammation, particularly musculoskeletal and locomotor conditions where a veterinarian selects an NSAID approach. The dosage form is designed for professional animal use and should be incorporated into a treatment or support plan only in accordance with the approved label and local registration.
From a functional perspective, Phenylbutazone is an NSAID that reduces prostaglandin synthesis and thereby decreases inflammatory pain, swelling and related discomfort. Its use requires careful attention to species, hydration status and gastrointestinal or renal risk. This profile explains why the product may be useful when a veterinarian wants to address a specific physiological or clinical need rather than treat signs without identifying their cause. According to available product information, target species include species authorized by the local product registration, traditionally including horses in many veterinary markets. Final case selection still depends on diagnosis, age, body weight, production stage and the presence of concurrent disease or medicines that could influence response or safety.
A key strength of Phenylbutazone 20% Inj. is the combination of a recognizable active profile with a veterinary dosage form suited to routine clinic or farm use. When selected for the right case, it can form part of a broader program intended to support or treat management of pain and inflammation, particularly musculoskeletal and locomotor conditions where a veterinarian selects an NSAID approach. It should not be presented as a universal answer to every animal showing the same clinical sign, because similar signs may arise from very different infectious, nutritional, metabolic or management-related causes.
Before using an NSAID, hydration, renal function and gastrointestinal risk should be considered because adverse effects are more likely in dehydrated animals or those with shock, ulceration or kidney impairment. Concurrent use of multiple NSAIDs or an NSAID with a corticosteroid should generally be avoided unless specifically directed. Analgesic therapy is most effective when combined with diagnosis and management of the condition that is causing pain or inflammation.
This copy is written for a veterinary product page, so it focuses on product identity, clinical or nutritional role, and practical positioning rather than reproducing a dosing leaflet. The product should always be used according to the locally approved label and package leaflet because authorized species, dosage schedules, withdrawal periods, contraindications and warnings may differ between markets. Appropriate veterinary use also depends on diagnosis, body weight, age, kidney and liver status, pregnancy or lactation, concurrent medicines and, for antimicrobials, the likely or confirmed susceptibility of the causative organism. Website information should therefore complement, not replace, professional veterinary advice and the manufacturer’s approved instructions.
For a website product page, Phenylbutazone 20% Inj. can be positioned as a specialized Kepro option with a defined formulation and a clear practical purpose. A complete page should ideally show the original pack, dosage form, principal active ingredients, registered target species and the general therapeutic or nutritional role. Detailed dosage, withdrawal and contraindication information should remain linked to the official leaflet or be provided by a veterinarian. This approach gives customers useful, professional information while keeping regulatory and clinical decisions where they belong: with the approved product information and qualified veterinary guidance.